pepi.ninja

Regulatory dispatch

503A vs 503B: how peptides get compounded in the US

Dateline
2026-05-03
Byline
pepi.ninja editorial
  • pcac
  • fda
  • compounding
  • primer
  • 503a
  • 503b

Background

Drug compounding in the United States operates under two parallel statutory pathways, both written into the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 503A covers the traditional pharmacy compounding most patients are familiar with — a state-licensed pharmacist preparing a personalized formulation for a specific patient. Section 503B covers outsourcing facilities, a category created in 2013 to bring high-volume sterile compounding under direct FDA oversight after the 2012 New England Compounding Center meningitis outbreak. The two pathways have different conditions, different oversight regimes, and — most importantly for peptides — different rules for which raw, “bulk” drug substances can lawfully be used.

Section 503A: traditional pharmacy compounding

Under section 503A, a compounded drug is exempt from the new-drug approval, adequate-directions-for-use, and current-good-manufacturing-practice provisions of the FD&C Act if specific conditions are met. The compounding must be performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, and the compound must be made for an identified individual patient based on a valid prescription (FDA — Section 503A).

The bulk-substance rule under 503A is strict. A bulk drug substance may be used only if at least one of three conditions applies: (1) it is the subject of an applicable USP or NF monograph, (2) it is a component of an FDA-approved drug, or (3) it appears on a list developed by FDA after consultation with the United States Pharmacopeia and the Pharmacy Compounding Advisory Committee — the so-called 503A Bulks List (FDA — 503A Bulks).

Section 503A also forbids compounding “regularly or in inordinate amounts” of any drug that is essentially a copy of a commercially available drug, and it bars compounding any drug withdrawn from the market for safety reasons.

Section 503B: outsourcing facilities

The Drug Quality and Security Act of 2013 created section 503B to address a gap that the meningitis outbreak had revealed — high-volume sterile compounding sold to hospitals and clinics across state lines, with no direct FDA inspection authority. A 503B outsourcing facility must register with the FDA, comply with current good manufacturing practice (cGMP) requirements similar to those for finished-drug manufacturers, submit to FDA inspection, and report adverse events and product information twice yearly (FDA — Section 503B).

In return, a 503B facility may compound drugs without patient-specific prescriptions and ship for office use across state lines. But its bulk-substance options are even narrower than those of a 503A pharmacy. According to the FDA, an outsourcing facility may not compound a drug from a bulk drug substance “unless it appears on FDA’s 503B bulks list or on FDA’s drug shortage list” (FDA — 503B Bulks). Bulk substances must also be accompanied by a valid certificate of analysis and manufactured by an FDA-registered establishment.

Inclusion on the 503B list requires demonstration of a “clinical need” — a higher and somewhat differently scoped standard than the 503A list, focused on whether the substance is needed in compounded form for a particular medical use that cannot be met by an FDA-approved alternative.

Peptides under both pathways

Most of the peptides currently driving regulatory and public attention — BPC-157, KPV, TB-500, MOTs-C, semaglutide analogues, and others — are not FDA-approved finished drugs and are not the subject of a USP or NF monograph. That means under section 503A, they can lawfully be compounded only if they appear on the 503A Bulks List, and under section 503B, only if they appear on the 503B list (or, transiently, on FDA’s drug-shortage list).

Many of these peptides were nominated for the 503A list in the original 2014–2015 nomination window, when FDA invited the public to submit substances for review. FDA placed several of them in “Category 2” under its interim policy — substances flagged with “significant safety risks” that the agency did not intend to include in a future enforcement-discretion category until a full PCAC review was complete.

In April 2026, FDA announced that several peptide substances — including BPC-157 and KPV — had been removed from Category 2 because the original nominations were withdrawn, and that the agency would consult the PCAC on whether to include them on the 503A Bulks List (FDA — July 23-24, 2026 PCAC meeting).

What’s at stake

For a 503A pharmacy, a “yes” PCAC recommendation followed by FDA rulemaking to add a peptide to the 503A Bulks List opens a regulated compounding pathway. A “no” effectively closes it: the substance is neither a USP-monograph drug nor a component of an FDA-approved product, leaving no statutory basis on which to compound it under 503A.

For a 503B outsourcing facility, the picture is even narrower. Even if a peptide reaches the 503A Bulks List, it must separately clear the 503B “clinical need” standard before it can be compounded by an outsourcing facility for non-patient-specific distribution. The two lists do not move in lockstep, and historically the 503B list has been considerably shorter than the 503A list.

The July 23-24, 2026 PCAC meeting is the first agency-level review of these specific peptide bulk substances under the new 503A nomination framework, and the recommendations made there will set the tone for any subsequent 503B clinical-need analyses.

Sources